Next-generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology

Histopathology

Volumn 66, Issue 2, 2015, Pages 215-224

  Le Mercier, Marie ^a   D'Haene, Nicky ^a   De Nève, Nancy ^a   Blanchard, Oriane ^a   Degand, Caroline ^a   Rorive, Sandrine ^a,b   Salmon, Isabelle ^a,b  

^a ERASME HOSPITAL   (Belgium)

^b Academie universitaire Wallonie Bruxelles   (Belgium)

Author keywords

Molecular diagnosis; Next generation sequencing; Thyroid cancer; Thyroid FNA

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CLINICAL ARTICLE; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; NEXT GENERATION SEQUENCING; ONCOGENE N RAS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID GLAND; THYROID NODULE; DNA SEQUENCE; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PROCEDURES;

ADULT; BIOPSY, FINE-NEEDLE; DNA MUTATIONAL ANALYSIS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; THYROID NODULE;

EID: 84925233233     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12461     Document Type: Article

References (56)

1. Yeung MJ, Serpell JW. Management of the solitary thyroid nodule. Oncologist 2008; 13; 105-112.
2. Hegedus L. Clinical practice. The thyroid nodule. N. Engl. J. Med. 2004; 351; 1764-1771.
3. Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19; 1167-1214.
4. Gharib H, Papini E, Paschke R et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and EuropeanThyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules. Endocr. Pract. 2010; 16(Suppl 1); 1-43.
5. Rorive S, D'Haene N, Fossion C et al. Ultrasound-guided fineneedle aspiration of thyroid nodules: stratification of malignancy risk using follicular proliferation grading, clinical and ultrasonographic features. Eur. J. Endocrinol./Eur. Fed. Endocr. Soc. 2010; 162; 1107-1115.
6. Layfield LJ, Cibas ES, Gharib H, Mandel SJ. Thyroid aspiration cytology: current status. CA-Cancer J. Clin. 2009; 59; 99-110.
7. Banks ND, Kowalski J, Tsai HL et al. A diagnostic predictor model for indeterminate or suspicious thyroid FNA samples. Thyroid 2008; 18; 933-941.
8. Nagy N, Decaestecker C, Kiss R et al. A pilot study for identifying at risk thyroid lesions by means of a decision tree run on clinicocytological variables. Int. J. Mol. Med. 1999; 4; 299-308.
9. Popowicz B, Klencki M, Lewinski A, Slowinska-Klencka D. The usefulness of sonographic features in selection of thyroid nodules for biopsy in relation to the nodule's size. Eur. J. Endocrinol./ Eur. Fed. Endocr. Soc. 2009; 161; 103-111.
10. Kwak JY, Han KH, Yoon JH et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology 2011; 260; 892-899.
11. Eszlinger M, Krogdahl A, Munz S et al. Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules. Thyroid 2014; 24; 305-313.
12. Xing M, Clark D, Guan H et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J. Clin. Oncol. 2009; 27; 2977-2982.
13. Nikiforov YE, Ohori NP, Hodak SP et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J. Clin. Endocrinol. Metab. 2011; 96; 3390-3397.
14. Nikiforov YE, Steward DL, Robinson-Smith TM et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J. Clin. Endocrinol. Metab. 2009; 94; 2092-2098.
15. Moses W, Weng J, Sansano I et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J. Surg. 2010; 34; 2589-2594.
16. Cantara S, Capezzone M, Marchisotta S et al. Impact of protooncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J. Clin. Endocrinol. Metab. 2010; 95; 1365-1369.
17. Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J. Clin. Endocrinol. Metab. 2011; 96; 2016-2026.
18. Ohori NP, Nikiforova MN, Schoedel KE et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of 'follicular lesion of undetermined significance/atypia of undetermined significance'. Cancer Cytopathol. 2010; 118; 17-23.
19. Alexander EK, Kennedy GC, Baloch ZW et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N. Engl. J. Med. 2012; 367; 705-715.
20. Eszlinger M, Paschke R. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol. Cell. Endocrinol. 2010; 322; 29-37.
21. Metzker ML. Sequencing technologies - the next generation. Nat. Rev. Genet. 2010; 11; 31-46.
22. Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin. Biochem. Rev. 2011; 32; 177-195.
23. Glenn TC. Field guide to next-generation DNA sequencers. Mol. Ecol. Resour. 2011; 11; 759-769.
24. Beadling C, Neff TL, Heinrich MC et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J. Mol. Diagn. 2013; 15; 171-176.
25. Singh RS, Wang HH. Eliminating the 'Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance' category from the Bethesda System for Reporting Thyroid Cytopathology. Am. J. Clin. Pathol. 2011; 136; 896-902.
26. Mahajan A, Lin X, Nayar R. Thyroid Bethesda reporting category, 'suspicious for papillary thyroid carcinoma', pitfalls and clues to optimize the use of this category. Cytopathology 2013; 24; 85-91.
27. Krane JF, Vanderlaan PA, Faquin WC, Renshaw AA. The atypia of undetermined significance/follicular lesion of undetermined significance: malignant ratio: a proposed performance measure for reporting in the Bethesda system for thyroid cytopathology. Cancer Cytopathol. 2012; 120; 111-116.
28. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinform. 2012; 14; 178-192.
29. Singh RR, Patel KP, Routbort MJ et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J. Mol. Diagn. 2013; 15; 607-622.
30. Kruger S, Emig M, Lohse P, Ehninger G, Hochhaus A, Schackert HK. The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians. Leukemia 2006; 20; 354-355; discussion 356-357.
31. Grabellus F, Worm K, Sheu SY, Siffert W, Schmid KW, Bachmann HS. The prevalence of the c-kit exon 10 variant, M541L, in aggressive fibromatosis does not differ from the general population. J. Clin. Pathol. 2011; 64; 1021-1024.
32. Michils G, Tejpar S, Fryns JP et al. Pathogenic mutations and rare variants of the APC gene identified in 75 Belgian patients with familial adenomatous polyposis by fluorescent enzymatic mutation detection (EMD). Eur. J. Hum. Genet. 2002; 10; 505-510.
33. Offit K, Gilad S, Paglin S et al. Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers. Clin. Cancer Res. 2002; 8; 3813-3819.
34. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16; 109-142.
35. McCourt CM, McArt DG, Mills K et al. Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS ONE 2013; 8; e69604.
36. Tuononen K, Maki-Nevala S, Sarhadi VK et al. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin- fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS. Genes Chromosom. Cancer 2013; 52; 503-511.
37. Scarpa A, Sikora K, Fassan M et al. Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS ONE 2013; 8; e80478.
38. Kanagal-Shamanna R, Portier BP, Singh RR et al. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod. Pathol. 2013; 27; 314-327.
39. Hadd AG, Houghton J, Choudhary A et al. Targeted, highdepth, next-generation sequencing of cancer genes in formalinfixed, paraffin-embedded and fine-needle aspiration tumor specimens. J. Mol. Diagn. 2013; 15; 234-247.
40. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J. Clin. Endocrinol. Metab. 2013; 98; E1852-E1860.
41. Gupta N, Dasyam AK, Carty SE et al. RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J. Clin. Endocrinol. Metab. 2013; 98; E914-E922.
42. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am. J. Clin. Pathol. 2003; 120; 71-77.
43. Burns JS, Blaydes JP, Wright PA et al. Stepwise transformation of primary thyroid epithelial cells by a mutant Ha-ras oncogene: an in vitro model of tumor progression. Mol. Carcinog. 1992; 6; 129-139.
44. Arora N, Scognamiglio T, Zhu B, Fahey TJ III. Do benign thyroid nodules have malignant potential? An evidence-based review World J. Surg. 2008; 32; 1237-1246.
45. Dahia PL, Marsh DJ, Zheng Z et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997; 57; 4710-4713.
46. Wang HM, Huang YW, Huang JS et al. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma. Ann. Surg. Oncol. 2007; 14; 3011-3018.
47. Hou P, Liu D, Shan Y et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin. Cancer Res. 2007; 13; 1161-1170.
48. Liu Z, Hou P, Ji M et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J. Clin. Endocrinol. Metab. 2008; 93; 3106-3116.
49. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer 2013; 13; 184-199.
50. Yang H, Ye D, Guan KL, Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin. Cancer Res. 2012; 18; 5562-5571.
51. Hemerly JP, Bastos AU, Cerutti JM. Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur. J. Endocrinol./Eur. Fed. Endocr. Soc. 2010; 163; 747-755.
52. Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem. Biophys. Res. Commun. 2010; 393; 555-559.
53. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol. 2011; 7; 569-580.
54. Soares P, Lima J, Preto A et al. Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Curr. Genomics 2011; 12; 609-617.
55. Sobrinho-Simoes M, Preto A, Rocha AS et al. Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch. 2005; 447; 787-793.
56. Greco A, Miranda C, Pierotti MA. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol. Cell. Endocrinol. 2010; 321; 44-49.